MCLA-129 + befotertinib

MCLA-129 + befotertinib is an investigational drug combination evaluated for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations. MCLA-129 is a bispecific monoclonal antibody that targets both the epidermal growth factor receptor (EGFR) and c-MET (hepatocyte growth factor receptor), inhibiting their signaling and enhancing antitumor immune responses (antibody-dependent cellular cytotoxicity/ADCC). Befotertinib is an orally available, third-generation, highly selective small molecule inhibitor of mutant EGFR (notably including T790M resistance mutation), which blocks EGFR-mediated tumor signaling. The combination aims to better suppress tumor growth by jointly targeting EGFR (including resistance mutations) and c-MET pathways, both of which commonly promote tumor proliferation and survival in NSCLC[1][4][5][6].

Brand names

Surmana

Other names

1835667-63-4UNII-0XT2CPR891UNII0XT2CPR891UNII 0XT2CPR891bispecific anti-EGFR/c-Met antibody plus befotertinib